The evolving landscape of antibody–drug conjugates: In depth analysis of recent research progress
Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …
Therapeutic applications of nanobiotechnology
Y Dutt, RP Pandey, M Dutt, A Gupta, A Vibhuti… - Journal of …, 2023 - Springer
Nanobiotechnology, as a novel and more specialized branch of science, has provided a
number of nanostructures such as nanoparticles, by utilizing the methods, techniques, and …
number of nanostructures such as nanoparticles, by utilizing the methods, techniques, and …
Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method
In response to infection or sterile insults, inflammatory programmed cell death is an essential
component of the innate immune response to remove infected or damaged cells …
component of the innate immune response to remove infected or damaged cells …
Phase II/III results of a trial of anti–tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis
T Takeuchi, M Kawanishi, M Nakanishi… - Arthritis & …, 2022 - Wiley Online Library
Objective To assess the efficacy and safety of subcutaneous administration of 30 mg or 80
mg of ozoralizumab plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) …
mg of ozoralizumab plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) …
CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin
J Ma, X Xu, C Fu, P Xia, M Tian, L Zheng… - Biomaterials …, 2022 - spj.science.org
Background It is highly desirable to develop new therapeutic strategies for gastric cancer
given the low survival rate despite improvement in the past decades. Cadherin 17 (CDH17) …
given the low survival rate despite improvement in the past decades. Cadherin 17 (CDH17) …
Nanobody: a small antibody with big implications for tumor therapeutic strategy
S Sun, Z Ding, X Yang, X Zhao, M Zhao… - International Journal …, 2021 - Taylor & Francis
The development of monoclonal antibody treatments for successful tumor-targeted therapies
took several decades. However, the efficacy of antibody-based therapy is still confined and …
took several decades. However, the efficacy of antibody-based therapy is still confined and …
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
M Babamohamadi, N Mohammadi, E Faryadi… - Cell Death & …, 2024 - nature.com
Cancer is one of the most common diseases and causes of death worldwide. Since common
treatment approaches do not yield acceptable results in many patients, developing …
treatment approaches do not yield acceptable results in many patients, developing …
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to …
Y Tanaka, M Kawanishi, M Nakanishi… - Modern …, 2023 - academic.oup.com
Objective To assess the efficacy and safety through a 52-week treatment with subcutaneous
ozoralizumab at 30 or 80 mg in patients with active rheumatoid arthritis despite methotrexate …
ozoralizumab at 30 or 80 mg in patients with active rheumatoid arthritis despite methotrexate …
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab'without methotrexate co-administration in patients with active rheumatoid arthritis: a …
Y Tanaka, M Kawanishi, M Nakanishi… - Modern …, 2023 - academic.oup.com
Objectives The aim is to assess the efficacy and safety of a 52-week subcutaneous
ozoralizumab treatment at 30 and 80 mg without methotrexate (MTX) in active rheumatoid …
ozoralizumab treatment at 30 and 80 mg without methotrexate (MTX) in active rheumatoid …
A nanobody‐on‐quantum dot displacement assay for rapid and sensitive quantification of the epidermal growth factor receptor (EGFR)
R Su, YT Wu, S Doulkeridou, X Qiu… - Angewandte Chemie …, 2022 - Wiley Online Library
Biosensing approaches that combine small, engineered antibodies (nanobodies) with
nanoparticles are often complicated. Here, we show that nanobodies with different C …
nanoparticles are often complicated. Here, we show that nanobodies with different C …